Clinical Trial Update: Sildenafil for Early Pulmonary Vascular Disease in Scleroderma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sildenafil for early pulmonary vascular disease in patients with systemic sclerosis (scleroderma) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Systemic Sclerosis

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: Johns Hopkins University | Conditions: Scleroderma, Mildly Elevated Pulmonary Pressures | Phase 2 | Status: RECRUITING